Skip to main content
Erschienen in: International Ophthalmology 5/2016

14.01.2016 | Review

New insights in diagnosis and treatment for Retinopathy of Prematurity

verfasst von: Linda A. Cernichiaro-Espinosa, Francisco J. Olguin-Manriquez, Andree Henaine-Berra, Gerardo Garcia-Aguirre, Hugo Quiroz-Mercado, Maria A. Martinez-Castellanos

Erschienen in: International Ophthalmology | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study was to review current perspectives on diagnosis and treatment of Retinopathy of Prematurity (ROP). We performed a systematic review of how much has been produced in research published online and on print regarding ROP in different settings around the world. Early Treatment for ROP (ETROP) classification is the currently accepted classification of ROP. Fluorescein angiography and spectral domain optical coherence tomography (SD-OCT) may eventually lead to changes in the definition of ROP, and as a consequence, they will serve as a guide for treatment. Intravitreal anti-VEGF therapy has proven to be more effective in terms of lowering recurrence, allowing growth of the peripheral retina, and diminishing the incidence of retinal detachment when proliferative ROP is diagnosed. Whether anti-VEGF plus laser are better than any of these therapies separately remains a subject of discussion. Telemedicine is evolving everyday to allow access to remote areas that do not count with a retina specialist for treatment. A management algorithm is proposed according to our reference center experience. ROP is an evolving subject, with a vulnerable population of study that, once treated with good results, leads to a reduction in visual disability and in consequence, in a lifetime improvement.
Literatur
1.
Zurück zum Zitat International Committee for the Classification of Retinopathy of Prematurity (2005) The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 123(7):991–999CrossRef International Committee for the Classification of Retinopathy of Prematurity (2005) The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 123(7):991–999CrossRef
3.
Zurück zum Zitat Klufas MA, Patel SN, Ryan MC et al (2015) Influence of fluorescein angiography on the diagnosis and management of retinopathy of prematurity. Ophthalmology 122(8):1601–1608PubMedPubMedCentralCrossRef Klufas MA, Patel SN, Ryan MC et al (2015) Influence of fluorescein angiography on the diagnosis and management of retinopathy of prematurity. Ophthalmology 122(8):1601–1608PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Gschliesser A, Stifter E, Neumayer T et al (2015) Inter-expert and Intra-expert Agreement on the Diagnosis and Treatment of Retinopathy of Prematurity. Am J Ophthalmol 160(3):553e3–560e3CrossRef Gschliesser A, Stifter E, Neumayer T et al (2015) Inter-expert and Intra-expert Agreement on the Diagnosis and Treatment of Retinopathy of Prematurity. Am J Ophthalmol 160(3):553e3–560e3CrossRef
5.
Zurück zum Zitat Patel SN, Klufas MA, Ryan MC et al (2015) Color fundus photography versus fluorescein angiography in identification of the macular center and zone in retinopathy of prematurity. Am J Ophthalmol 159(5):950e2–957e2CrossRef Patel SN, Klufas MA, Ryan MC et al (2015) Color fundus photography versus fluorescein angiography in identification of the macular center and zone in retinopathy of prematurity. Am J Ophthalmol 159(5):950e2–957e2CrossRef
6.
Zurück zum Zitat Ng EY, Lanigan B, O’Keefe M (2006) Fundus fluorescein angiography in the screening for and management of retinopathy of prematurity. J Pediatr Ophthalmol Strabismus 43(2):85–90PubMed Ng EY, Lanigan B, O’Keefe M (2006) Fundus fluorescein angiography in the screening for and management of retinopathy of prematurity. J Pediatr Ophthalmol Strabismus 43(2):85–90PubMed
7.
Zurück zum Zitat Yokoi T, Hiraoka M, Miyamoto M et al (2009) Vascular abnormalities in aggressive posterior retinopathy of prematurity detected by fluorescein angiography. Ophthalmology 116(7):1377–1382PubMedCrossRef Yokoi T, Hiraoka M, Miyamoto M et al (2009) Vascular abnormalities in aggressive posterior retinopathy of prematurity detected by fluorescein angiography. Ophthalmology 116(7):1377–1382PubMedCrossRef
8.
Zurück zum Zitat Henaine-Berra A, Garcia-Aguirre G, Quiroz-Mercado H, Martinez-Castellanos MA (2014) Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy. J AAPOS 18(2):120–123PubMedCrossRef Henaine-Berra A, Garcia-Aguirre G, Quiroz-Mercado H, Martinez-Castellanos MA (2014) Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy. J AAPOS 18(2):120–123PubMedCrossRef
9.
Zurück zum Zitat Alba-Orozco A, Rodríguez-Quiñones L, Sepúlveda H, Morales-Canton V, Martínez-Castellanos MA. Fluorescein Angiography Differences Between Retinopathy of Prematurity and Retinopathy Induced by Oxygen in Preterm Newborns. ARVO 2014 Anual Meeting Abstracts Alba-Orozco A, Rodríguez-Quiñones L, Sepúlveda H, Morales-Canton V, Martínez-Castellanos MA. Fluorescein Angiography Differences Between Retinopathy of Prematurity and Retinopathy Induced by Oxygen in Preterm Newborns. ARVO 2014 Anual Meeting Abstracts
10.
Zurück zum Zitat Vajzovic L, Hendrickson AE, O’Connell RV, et al. (2012) Maturation of the human fovea: correlation of spectral-domain optical coherence tomography findings with histology. Am J Ophthalmol. 154(5):779–89 e2 Vajzovic L, Hendrickson AE, O’Connell RV, et al. (2012) Maturation of the human fovea: correlation of spectral-domain optical coherence tomography findings with histology. Am J Ophthalmol. 154(5):779–89 e2
11.
Zurück zum Zitat Cernichiaro-Espinosa LA, Garcia-Huerta MM, Giordano VE et al (2014) Comparison of iridocorneal angle in infants with retinopathy of prematurity and healthy infants using spectral domain optical coherence tomography. J AAPOS 18(4):344–346PubMedCrossRef Cernichiaro-Espinosa LA, Garcia-Huerta MM, Giordano VE et al (2014) Comparison of iridocorneal angle in infants with retinopathy of prematurity and healthy infants using spectral domain optical coherence tomography. J AAPOS 18(4):344–346PubMedCrossRef
12.
Zurück zum Zitat Vinekar A, Avadhani K, Sivakumar M, et al. (2012) Macular edema in premature infants. Ophthalmology. 119(6):1288-9 e1; author reply 9-90 e1 Vinekar A, Avadhani K, Sivakumar M, et al. (2012) Macular edema in premature infants. Ophthalmology. 119(6):1288-9 e1; author reply 9-90 e1
13.
Zurück zum Zitat Vinekar A, Avadhani K, Sivakumar M et al (2011) Understanding clinically undetected macular changes in early retinopathy of prematurity on spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci 52(8):5183–5188PubMedCrossRef Vinekar A, Avadhani K, Sivakumar M et al (2011) Understanding clinically undetected macular changes in early retinopathy of prematurity on spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci 52(8):5183–5188PubMedCrossRef
14.
Zurück zum Zitat Vinekar A, Mangalesh S, Jayadev C et al (2015) Macular edema in Asian Indian premature infants with retinopathy of prematurity: impact on visual acuity and refractive status after 1-year. Indian J Ophthalmol 63(5):432–437PubMedPubMedCentralCrossRef Vinekar A, Mangalesh S, Jayadev C et al (2015) Macular edema in Asian Indian premature infants with retinopathy of prematurity: impact on visual acuity and refractive status after 1-year. Indian J Ophthalmol 63(5):432–437PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Wu WC, Shih CP, Wang NK et al (2013) Choroidal thickness in patients with a history of retinopathy of prematurity. JAMA Ophthalmol 131(11):1451–1458PubMedCrossRef Wu WC, Shih CP, Wang NK et al (2013) Choroidal thickness in patients with a history of retinopathy of prematurity. JAMA Ophthalmol 131(11):1451–1458PubMedCrossRef
16.
Zurück zum Zitat Erol MK, Ozdemir O, Turgut Coban D et al (2014) Macular findings obtained by spectral domain optical coherence tomography in retinopathy of prematurity. J Ophthalmol 2014:468653PubMedPubMedCentralCrossRef Erol MK, Ozdemir O, Turgut Coban D et al (2014) Macular findings obtained by spectral domain optical coherence tomography in retinopathy of prematurity. J Ophthalmol 2014:468653PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Cryotherapy for Retinopathy of Prematurity Cooperative Group (1988) Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol 106(4):471–479CrossRef Cryotherapy for Retinopathy of Prematurity Cooperative Group (1988) Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol 106(4):471–479CrossRef
18.
Zurück zum Zitat Cryotherapy for Retinopathy of Prematurity Cooperative Group (2001) Multicenter trial of cryotherapy for retinopathy of prematurity: ophthalmological outcomes at 10 years. Arch Ophthalmol 119(8):1110–1118CrossRef Cryotherapy for Retinopathy of Prematurity Cooperative Group (2001) Multicenter trial of cryotherapy for retinopathy of prematurity: ophthalmological outcomes at 10 years. Arch Ophthalmol 119(8):1110–1118CrossRef
19.
Zurück zum Zitat STOP-ROP Multicenter Study Group (2000) Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics 105(2):295–310CrossRef STOP-ROP Multicenter Study Group (2000) Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics 105(2):295–310CrossRef
20.
Zurück zum Zitat Reynolds JD, Hardy RJ, Kennedy KA, Spencer R, van Heuven WA, Fielder ARs, Light reduction in retinopathy of prematurity (LIGHT-ROP) Cooperative Group (1998) Lack of efficacy of light reduction in preventing retinopathy of prematurity. N Engl J Med 338(22):1572–1576PubMedCrossRef Reynolds JD, Hardy RJ, Kennedy KA, Spencer R, van Heuven WA, Fielder ARs, Light reduction in retinopathy of prematurity (LIGHT-ROP) Cooperative Group (1998) Lack of efficacy of light reduction in preventing retinopathy of prematurity. N Engl J Med 338(22):1572–1576PubMedCrossRef
21.
Zurück zum Zitat Good WV, Early Treatment for Retinopathy of Prematurity Cooperative G (2004) Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 102: 233–248; discussion 48-50 Good WV, Early Treatment for Retinopathy of Prematurity Cooperative G (2004) Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 102: 233–248; discussion 48-50
22.
Zurück zum Zitat Early Treatment For Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121(12):1684–1694PubMedCrossRef Early Treatment For Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121(12):1684–1694PubMedCrossRef
23.
Zurück zum Zitat Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) Group B-RC. Efficacy of intravitreal bevacizumab for stage 3 + retinopathy of prematurity. N Engl J Med 364(7):603–615PubMedPubMedCentralCrossRef Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) Group B-RC. Efficacy of intravitreal bevacizumab for stage 3 + retinopathy of prematurity. N Engl J Med 364(7):603–615PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Pertl L, Steinwender G, Mayer C et al (2015) A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity. PLoS ONE 10(6):e0129383PubMedPubMedCentralCrossRef Pertl L, Steinwender G, Mayer C et al (2015) A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity. PLoS ONE 10(6):e0129383PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Vinekar A, Jayadev C, Mangalesh S et al (2015) Comparing the outcome of single versus multiple session laser photoablation of flat neovascularization in zone 1 aggressive posterior retinopathy of prematurity: a prospective randomized study. Retina 35(10):2130–2136PubMedCrossRef Vinekar A, Jayadev C, Mangalesh S et al (2015) Comparing the outcome of single versus multiple session laser photoablation of flat neovascularization in zone 1 aggressive posterior retinopathy of prematurity: a prospective randomized study. Retina 35(10):2130–2136PubMedCrossRef
26.
Zurück zum Zitat Kim J, Kim SJ, Chang YS, Park WS (2014) Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity. Retina 34(1):77–82PubMedCrossRef Kim J, Kim SJ, Chang YS, Park WS (2014) Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity. Retina 34(1):77–82PubMedCrossRef
27.
Zurück zum Zitat Castellanos MA, Schwartz S, Garcia-Aguirre G, Quiroz-Mercado H (2013) Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Br J Ophthalmol 97(7):816–819PubMedCrossRef Castellanos MA, Schwartz S, Garcia-Aguirre G, Quiroz-Mercado H (2013) Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Br J Ophthalmol 97(7):816–819PubMedCrossRef
28.
Zurück zum Zitat Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML, Salazar-Teran N, Chan RV (2008) Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 28(3 Suppl):S19–S25PubMedCrossRef Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML, Salazar-Teran N, Chan RV (2008) Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 28(3 Suppl):S19–S25PubMedCrossRef
29.
Zurück zum Zitat Salman AG, Said AM (2015) Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity. Ophthalmic Res 53(1):15–20PubMedCrossRef Salman AG, Said AM (2015) Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity. Ophthalmic Res 53(1):15–20PubMedCrossRef
30.
31.
Zurück zum Zitat Martinez-Castellanos MA, Domenzain-Afendulis JL, Hernandez-Rojas ML et al (2007) Safety and efficacy of intravitreal Bevacizumab for retinopathy of prematurity. IOVS 48(13):85 Martinez-Castellanos MA, Domenzain-Afendulis JL, Hernandez-Rojas ML et al (2007) Safety and efficacy of intravitreal Bevacizumab for retinopathy of prematurity. IOVS 48(13):85
32.
Zurück zum Zitat Olguin-Manriquez FJ, Martínez-Castellanos MA. Efectividad de la terapia antiangiogénica intravítrea como adyuvante en la retinopatía del prematuro. Paper presentation. PAAO Meeting 2015 Bogotá, Colombia Olguin-Manriquez FJ, Martínez-Castellanos MA. Efectividad de la terapia antiangiogénica intravítrea como adyuvante en la retinopatía del prematuro. Paper presentation. PAAO Meeting 2015 Bogotá, Colombia
33.
Zurück zum Zitat Martinez-Castellanos MA, Schwartz S, Hernandez-Rojas ML et al (2013) Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up. Retina 33(2):329–338PubMedCrossRef Martinez-Castellanos MA, Schwartz S, Hernandez-Rojas ML et al (2013) Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up. Retina 33(2):329–338PubMedCrossRef
34.
Zurück zum Zitat Wong RK, Hubschman S, Tsui I (2015) Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina 35(4):675–680PubMedCrossRef Wong RK, Hubschman S, Tsui I (2015) Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina 35(4):675–680PubMedCrossRef
35.
Zurück zum Zitat Chen SN, Lian I, Hwang YC et al (2015) Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab. Retina 35(4):667–674PubMedCrossRef Chen SN, Lian I, Hwang YC et al (2015) Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab. Retina 35(4):667–674PubMedCrossRef
36.
Zurück zum Zitat Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML, Salazar-Teran N, Chan RV (2008) Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 28(3 Suppl):S19–S25PubMedCrossRef Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML, Salazar-Teran N, Chan RV (2008) Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 28(3 Suppl):S19–S25PubMedCrossRef
37.
Zurück zum Zitat Nudleman E, Robinson J, Rao P, Drenser KA, Capone A, Trese MT (2015) Long-term outcomes on lens clarity after lens-sparing vitrectomy for retinopathy of prematurity. Ophthalmology 122(4):755–759PubMedCrossRef Nudleman E, Robinson J, Rao P, Drenser KA, Capone A, Trese MT (2015) Long-term outcomes on lens clarity after lens-sparing vitrectomy for retinopathy of prematurity. Ophthalmology 122(4):755–759PubMedCrossRef
38.
Zurück zum Zitat Lakhanpal RR, Davis GH, Sun RL, Albini TA, Holz ER (2006) Lens clarity after 3-port lens-sparing vitrectomy in stage 4A and 4B retinal detachments secondary to retinopathy of prematurity. Arch Ophthalmol 124(1):20–23PubMedCrossRef Lakhanpal RR, Davis GH, Sun RL, Albini TA, Holz ER (2006) Lens clarity after 3-port lens-sparing vitrectomy in stage 4A and 4B retinal detachments secondary to retinopathy of prematurity. Arch Ophthalmol 124(1):20–23PubMedCrossRef
39.
Zurück zum Zitat Wu WC, Lai CC, Lin RI et al (2011) Modified 23-gauge vitrectomy system for stage 4 retinopathy of prematurity. Arch Ophthalmol 129(10):1326–1331PubMedCrossRef Wu WC, Lai CC, Lin RI et al (2011) Modified 23-gauge vitrectomy system for stage 4 retinopathy of prematurity. Arch Ophthalmol 129(10):1326–1331PubMedCrossRef
40.
Zurück zum Zitat Carvounis PE, Poll J, Weikert MP, Wilhelmus K, Lakhanpal RR, Holz ER (2010) Refractive outcomes of lens-sparing vitrectomy for retinopathy of prematurity. Arch Ophthalmol 128(7):843–846PubMedCrossRef Carvounis PE, Poll J, Weikert MP, Wilhelmus K, Lakhanpal RR, Holz ER (2010) Refractive outcomes of lens-sparing vitrectomy for retinopathy of prematurity. Arch Ophthalmol 128(7):843–846PubMedCrossRef
41.
Zurück zum Zitat Kychenthal A, Dorta P (2010) Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity. Retina 30(4 Suppl):S32–S36PubMedCrossRef Kychenthal A, Dorta P (2010) Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity. Retina 30(4 Suppl):S32–S36PubMedCrossRef
42.
Zurück zum Zitat Kychenthal A, Dorta P (2008) 25-gauge lens-sparing vitrectomy for stage 4A retinopathy of prematurity. Retina 28(3 Suppl):S65–S68PubMedCrossRef Kychenthal A, Dorta P (2008) 25-gauge lens-sparing vitrectomy for stage 4A retinopathy of prematurity. Retina 28(3 Suppl):S65–S68PubMedCrossRef
43.
Zurück zum Zitat El Rayes EN, Vinekar A, Capone A Jr (2008) Three-year anatomic and visual outcomes after vitrectomy for stage 4B retinopathy of prematurity. Retina 28(4):568–572PubMedCrossRef El Rayes EN, Vinekar A, Capone A Jr (2008) Three-year anatomic and visual outcomes after vitrectomy for stage 4B retinopathy of prematurity. Retina 28(4):568–572PubMedCrossRef
44.
Zurück zum Zitat Wu C, Petersen RA, VanderVeen DK (2006) RetCam imaging for retinopathy of prematurity screening. J AAPOS 10(2):107–111PubMedCrossRef Wu C, Petersen RA, VanderVeen DK (2006) RetCam imaging for retinopathy of prematurity screening. J AAPOS 10(2):107–111PubMedCrossRef
45.
Zurück zum Zitat Vinekar A, Gilbert C, Dogra M et al (2014) The KIDROP model of combining strategies for providing retinopathy of prematurity screening in underserved areas in India using wide-field imaging, tele-medicine, non-physician graders and smart phone reporting. Indian J Ophthalmol 62(1):41–49PubMedPubMedCentralCrossRef Vinekar A, Gilbert C, Dogra M et al (2014) The KIDROP model of combining strategies for providing retinopathy of prematurity screening in underserved areas in India using wide-field imaging, tele-medicine, non-physician graders and smart phone reporting. Indian J Ophthalmol 62(1):41–49PubMedPubMedCentralCrossRef
46.
Zurück zum Zitat Ells AL, Holmes JM, Astle WF et al (2003) Telemedicine approach to screening for severe retinopathy of prematurity: a pilot study. Ophthalmology 110(11):2113–2117PubMedCrossRef Ells AL, Holmes JM, Astle WF et al (2003) Telemedicine approach to screening for severe retinopathy of prematurity: a pilot study. Ophthalmology 110(11):2113–2117PubMedCrossRef
47.
Zurück zum Zitat Chiang MF, Keenan JD, Starren J et al (2006) Accuracy and reliability of remote retinopathy of prematurity diagnosis. Arch Ophthalmol 124(3):322–327PubMedCrossRef Chiang MF, Keenan JD, Starren J et al (2006) Accuracy and reliability of remote retinopathy of prematurity diagnosis. Arch Ophthalmol 124(3):322–327PubMedCrossRef
48.
Zurück zum Zitat Photographic Screening for Retinopathy of Prematurity Cooperative Group (2008) The photographic screening for retinopathy of prematurity study (photo-ROP). Primary outcomes. Retina 28(3 Suppl):S47–54CrossRef Photographic Screening for Retinopathy of Prematurity Cooperative Group (2008) The photographic screening for retinopathy of prematurity study (photo-ROP). Primary outcomes. Retina 28(3 Suppl):S47–54CrossRef
Metadaten
Titel
New insights in diagnosis and treatment for Retinopathy of Prematurity
verfasst von
Linda A. Cernichiaro-Espinosa
Francisco J. Olguin-Manriquez
Andree Henaine-Berra
Gerardo Garcia-Aguirre
Hugo Quiroz-Mercado
Maria A. Martinez-Castellanos
Publikationsdatum
14.01.2016
Verlag
Springer Netherlands
Erschienen in
International Ophthalmology / Ausgabe 5/2016
Print ISSN: 0165-5701
Elektronische ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-016-0177-8

Weitere Artikel der Ausgabe 5/2016

International Ophthalmology 5/2016 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Die überschießende Wundheilung in der filtrierenden Glaukomchirurgie ist ein zentraler Faktor für ein operatives Versagen. Nach der Einführung der Trabekulektomie in den 1960er-Jahren wurden viele Faktoren erkannt, die mit einer vermehrten …

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.